Skip to main content

Table 2 Proposed ATTR staging utilizing the staging tool proposed by Gillmore et al. [67]

From: Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers

Number of abnormal laboratory tests Stage (according to revised staging system) Median Overall Survival (months) 5-year Survival
0 I 69.2 63%
1 II 46.7 37%
2 III 24.1 19%
  1. (Laboratory tests: eGFR< 45 ml/min/1.73 m2, NT-proBNP > 3000 ng/L)